Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 7/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.37 |
| ▸ | TLR2 | O60603 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081558 | 0.78 | CCR5 (0.51) | CCR5 | |
| SCHEMBL5081555 | 0.70 | CCR5 (0.51) | CCR5 | |
| SCHEMBL4465064 | 0.70 | CCR5 (0.53) | CCR5 | |
| SCHEMBL4461843 | 0.70 | CCR5 (0.60) | CCR5 | |
| SCHEMBL4465069 | 0.68 | CCR5 (0.51) | CCR5 | |
| SCHEMBL4458354 | 0.65 | CCR5 (0.56) | CCR5 | |
| SCHEMBL7369382 | 0.65 | TSHR (0.46) | FKBP1ATSHR | |
| SCHEMBL23655138 | 0.65 | TSHR (0.56) | FKBP1ATSHR | |
| SCHEMBL22253312 | 0.64 | TSHR (0.43) | TSHR | |
| SCHEMBL24433396 | 0.64 | TSHR (0.43) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538122-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2009-05-26 | — | — | US | disclosed |
| US-20080139544-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2008-06-12 | — | — | US | disclosed |
| US-20050176703-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2005-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139544-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885FKBP1A 942/4885TLR2 32/4885 |
| US-20050176703-A1 | Heterocyclic antiviral compounds | CCR5, CCR3, CCR1 | CCR5 1/4885FKBP1A 942/4885TLR2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.